This assay uses reverse transcriptase polymerase chain reaction to determine expression levels of 16 cancer related and 5 control genes from the resected tumor specimen, which are then incorporated into an algorithm to provide the clinician with a RS and applied clinically to guide chemoendocrine prescription for early-stage ER+/HER2− disease [5]. This evidence concerns the gene ESR1 and neoplasm.